Santen RJ - Search Results

1

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.

Lipton A, Demers LM, Harvey HA, Kambic KB, Grossberg H, Brady C, Adlercruetz H, Trunet PF, Santen RJ. Lipton A, et al. Among authors: santen rj. Cancer. 1995 Apr 15;75(8):2132-8. doi: 10.1002/1097-0142(19950415)75:8<2132::aid-cncr2820750816>3.0.co;2-u. Cancer. 1995. PMID: 7697604 Clinical Trial.

2

Correlation of aromatase activity with histological differentiation of breast cancer--a morphometric analysis.

Lipton A, Santen RJ, Santner SJ, Harvey HA, White-Hershey D, Bartholomew MJ, Sharkey FE. Lipton A, et al. Among authors: santen rj. Breast Cancer Res Treat. 1988 Sep;12(1):31-5. doi: 10.1007/BF01805737. Breast Cancer Res Treat. 1988. PMID: 3196885

3

Marked heterogeneity of aromatase activity in human malignant melanoma tissue.

Santen RJ, Santner SJ, Harvey HA, Lipton A, Simmonds M, Feil PD, Manders E, Davis TS. Santen RJ, et al. Eur J Cancer Clin Oncol. 1988 Dec;24(12):1811-6. doi: 10.1016/0277-5379(88)90090-9. Eur J Cancer Clin Oncol. 1988. PMID: 3220078

4

Aromatase activity in primary and metastatic human breast cancer.

Lipton A, Santner SJ, Santen RJ, Harvey HA, Feil PD, White-Hershey D, Bartholomew MJ, Antle CE. Lipton A, et al. Among authors: santen rj. Cancer. 1987 Feb 15;59(4):779-82. doi: 10.1002/1097-0142(19870215)59:4<779::aid-cncr2820590419>3.0.co;2-u. Cancer. 1987. PMID: 3802035

5

Aromatase inhibitor development for treatment of breast cancer.

Masamura S, Adlercreutz H, Harvey H, Lipton A, Demers LM, Santen RJ, Santner SJ. Masamura S, et al. Among authors: santen rj. Breast Cancer Res Treat. 1995;33(1):19-26. doi: 10.1007/BF00666067. Breast Cancer Res Treat. 1995. PMID: 7749129 Review.

6

The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.

Demers LM, Lipton A, Harvey HA, Hanagan J, Mulagha M, Santen RJ. Demers LM, et al. Among authors: santen rj. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):683-5. doi: 10.1016/0960-0760(93)90282-2. J Steroid Biochem Mol Biol. 1993. PMID: 8386541 Clinical Trial.

7

The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.

Demers LM, Lipton A, Harvey HA, Kambic KB, Grossberg H, Brady C, Santen RJ. Demers LM, et al. Among authors: santen rj. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):687-91. doi: 10.1016/0960-0760(93)90283-3. J Steroid Biochem Mol Biol. 1993. PMID: 8476785 Clinical Trial.

8

Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat.

Sinha S, Kaseta J, Santner SJ, Demers LM, Bremmer WJ, Santen RJ. Sinha S, et al. Among authors: santen rj. Breast Cancer Res Treat. 1998 Mar;48(1):45-51. doi: 10.1023/a:1005937900788. Breast Cancer Res Treat. 1998. PMID: 9541188

9

Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.

Costa LA, Kopreski MS, Demers LM, Chinchilli VM, Santen RJ, Harvey HA, Lipton A. Costa LA, et al. Among authors: santen rj. Cancer. 1999 Jan 1;85(1):100-3. doi: 10.1002/(sici)1097-0142(19990101)85:1<100::aid-cncr14>3.0.co;2-5. Cancer. 1999. PMID: 9921980

10

Aromatase within the breast.

Yue W, Santen RJ, Wang JP, Hamilton CJ, Demers LM. Yue W, et al. Among authors: santen rj. Endocr Relat Cancer. 1999 Jun;6(2):157-64. doi: 10.1677/erc.0.0060157. Endocr Relat Cancer. 1999. PMID: 10731104

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

369 results

Search Page